论文部分内容阅读
[目的]研究阿罗洛尔治疗肝硬化患者门静脉高压的临床疗效。[方法]研究对象选取济南军区总医院2015年10月~2016年12月间收治的肝硬化伴门静脉高压患者102例,采用随机数字法将其分为对照组和观察组,每组各51例。对照组患者给予普萘洛尔治疗,观察组患者给予阿罗洛尔治疗。比较2组患者治疗前后的门静脉和脾静脉血流量、肝功能指标及血流动力学指标,同时比较不良反应发生率。[结果]治疗后,观察组的门静脉和脾静脉血流量均明显低于对照组(P<0.01),TBiL、ALB及ALT值均明显低于对照组(P<0.01),HVPG、WHVP均明显低于对照组(P<0.01),FHVP比较差异无统计学意义;2组患者的不良反应发生率比较差异无统计学意义。[结论]阿罗洛尔治疗肝硬化门静脉高压患者的临床疗效显著,可明显降低门静脉及脾静脉血流量,改善患者血流动力学,促进肝脏功能恢复,且治疗安全性较高,值得在临床推广。
[Objective] To study the clinical effect of arotinolol in the treatment of portal hypertension in patients with liver cirrhosis. [Methods] A total of 102 patients with cirrhosis and portal hypertension who were admitted to Jinan Military General Hospital from October 2015 to December 2016 were selected and randomly divided into control group and observation group, with 51 cases in each group . Patients in the control group were treated with propranolol, and patients in the observation group were treated with arotinolol. The portal vein and splenic vein blood flow, liver function indexes and hemodynamic indexes of two groups before and after treatment were compared. At the same time, the incidence of adverse reactions was compared. [Results] After treatment, the blood flow of portal vein and splenic vein in the observation group was significantly lower than that of the control group (P <0.01), TBiL, ALB and ALT were significantly lower than the control group (P <0.01), HVPG and WHVP were significantly Lower than the control group (P <0.01), FHVP no significant difference between the two groups of patients with adverse reactions was no significant difference in the incidence. [Conclusion] The clinical efficacy of arotinolol in the treatment of patients with cirrhosis and portal hypertension is significant, which can significantly reduce the blood flow in the portal vein and splenic vein, improve the patient’s hemodynamics and promote the recovery of the liver function, and the treatment is safe and worthy of clinical treatment Promotion.